Related Experiment Video
Updated: Sep 7, 2025

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells
Sherman S Leung1,2, Danielle J Borg1,3, Domenica A McCarthy1
1Glycation and Diabetes, Mater Research, The University of Queensland and Translational Research Institute, Brisbane, Australia.
Short-term administration of soluble receptor for advanced glycation end products (sRAGE) prevented murine diabetes by increasing regulatory T cells (Tregs). sRAGE treatment expanded functional human Tregs, highlighting its potential as a reproducible diabetes therapy.
Area of Science:
- Immunology
- Endocrinology
- Diabetes Research
Background:
- Type 1 diabetes is an autoimmune disease lacking a cure.
- The reproducibility crisis hinders clinical translation of potential diabetes therapeutics.
Purpose of the Study:
- To investigate the therapeutic potential of soluble receptor for advanced glycation end products (sRAGE) in preventing type 1 diabetes.
- To elucidate the mechanisms by which sRAGE impacts regulatory T cells (Tregs) and immune function in diabetes models.
Main Methods:
- Administration of sRAGE to mice in independent research centers.
- Assessment of Treg populations in islets, pancreatic lymph nodes, and spleen.
- Evaluation of Treg function in vitro using human Tregs and RAGE ligands.
- Utilized Treg depletion and RAGE knockout mouse models.
Main Results:
- sRAGE treatment protected against murine diabetes, with reproducible efficacy across two research centers.
- sRAGE administration increased the number and function of regulatory T cells (Tregs) within the pancreas and spleen.
- In vitro studies confirmed sRAGE expands functional human Tregs by reversing RAGE ligand-induced suppression.
- Diabetes protection was dependent on Tregs and RAGE antagonism.
Conclusions:
- sRAGE demonstrates reproducible efficacy in preventing experimental diabetes.
- sRAGE enhances Treg function and expansion, offering a promising therapeutic strategy.
- These findings position sRAGE as a potential treatment to prevent type 1 diabetes.
More Related Videos
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Diabetes Mellitus: Type 2 and Gestational
Psychoneuroimmunology: Diabetes and Cancer
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...

